Timur Ivannikov
Stock Analyst at Cantor Fitzgerald
(1.05)
# 3,608
Out of 4,854 analysts
7
Total ratings
66.67%
Success rate
-13.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Timur Ivannikov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris | Maintains: Overweight | $28 → $25 | $16.23 | +54.08% | 1 | May 14, 2025 | |
| ATXS Astria Therapeutics | Reiterates: Overweight | $47 | $5.22 | +800.38% | 1 | May 14, 2025 | |
| GOSS Gossamer Bio | Downgrades: Market Perform | $5 | $1.26 | +296.83% | 2 | Mar 7, 2023 | |
| ANAB AnaptysBio | Downgrades: Market Perform | n/a | $21.14 | - | 1 | Jan 6, 2023 | |
| RCKT Rocket Pharmaceuticals | Initiates: Outperform | $22 | $2.77 | +694.22% | 1 | Jul 8, 2022 | |
| APLS Apellis Pharmaceuticals | Maintains: Strong Buy | $112 → $114 | $19.10 | +496.86% | 1 | Mar 1, 2022 |
Pharvaris
May 14, 2025
Maintains: Overweight
Price Target: $28 → $25
Current: $16.23
Upside: +54.08%
Astria Therapeutics
May 14, 2025
Reiterates: Overweight
Price Target: $47
Current: $5.22
Upside: +800.38%
Gossamer Bio
Mar 7, 2023
Downgrades: Market Perform
Price Target: $5
Current: $1.26
Upside: +296.83%
AnaptysBio
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $21.14
Upside: -
Rocket Pharmaceuticals
Jul 8, 2022
Initiates: Outperform
Price Target: $22
Current: $2.77
Upside: +694.22%
Apellis Pharmaceuticals
Mar 1, 2022
Maintains: Strong Buy
Price Target: $112 → $114
Current: $19.10
Upside: +496.86%